Currently, therapy for squamous cancer (SqC) is unsatisfactory. Staphylococcal enterotoxin B (SEB) has strong immune regulatory activity. This study tests the hypothesis that SEB enforces the effect of immunotherapy on SqC growth in a mouse model. C3H/HeN mice and the SqC cell line squamous cell carcinoma VII were used to create an SqC mouse model. Immune cell assessment was performed by flow cytometry. Real-time RT-PCR and western blotting were used to evaluate target molecule expression. An apoptosis assay was used to assess the suppressive effect of T helper-9 (Th9) cells on the SqC cells. The results showed that immunotherapy consisting of SEB plus SqC antigen significantly inhibited SqC growth in the mice. The frequency of Th9 cells was markedly increased in the SqC tissue and mouse spleens after treatment. SEB markedly increased the levels of signal transducer and activator of transcription 5 phosphorylation and the expression of histone deacetylase-1 (HDAC1) and PU
INTRODUCTION
Squamous cancer (SqC) is one of the most common cancers in humans. The squamous cell is a type of epithelial cell. Although SqC is one of the major forms of skin cancer, it also occurs in the mucosa of the digestive tract, lungs, and other areas of the body. It has been reported that 90% of cases of head and neck cancer, including cancer of the mouth, nasal cavity, nasopharynx, throat and associated structures are SqC. 1 However, SqC pathogenesis is unclear. 2 The early diagnosis of SqC is sometimes difficult; indeed, SqC located in regions such as the rhinosinusesis often diagnosed in its advanced stages. 3 Currently, the therapeutic effects on SqC are not satisfactory. 4 A number of treatments have been used to treat SqC. Radiotherapy is one of the useful treatments; however, its major drawback is the development of radio resistance. 5 Chemotherapy is another common option for SqC treatment. However, drug resistance may also develop in SqC cells. 6 Surgical treatment is another option for some SqC patients, but the indications in advanced cases are limited. Immunotherapy has been used for the treatment of SqC in conjunction with other therapeutic treatments. 7 The purpose of immunotherapy is to induce antitumor immune cells, such as CD8 1 cytotoxic T cells, Th1 cells, Th2 cells, natural killer (NK) cells, and NKT cells. These anti-tumor immune cells induce cancer cell death through apoptosis or the release of antitumor molecules capable of inducing cancer cell death. 8 For example, our previous work has indicated that the laryngeal cancer-derived matrix metalloproteinase-9 facilitates the development of a specific anti-laryngeal cancer response.
Cumulative evidence has indicated that IL-9 plays a critical role in Th2-dominant immune responses, such as allergic asthma. 11 IL-9 in tumor tissues has been reported to contribute to anticancer functions by triggering the activation of dendritic cells (DCs), mast cells, NK cells, and CD8 T cells to mount an antitumor immune response. 12 However, the mechanism by which IL-9-producing cells are generated in cancer-bearing subjects has not been elucidated.
Staphylococcal enterotoxin B (SEB), an exotoxin of staphylococcus aureus, is a superantigen. One unique feature of SEB is that it activates T cells via cross-linking the Vb domain of the T-cell receptor to the major histocompatibility complex II (MHC II) in antigen-presenting cells. This feature can cause massive T-cell activation. 13 The basic mechanism of immunotherapy is to induce a specific immune response, including the induction of specific immune effector T cells, to suppress target tissues and cells. By using SEB as an adjuvant, we successfully induced antigen-specific Th2 pattern-inflammation in the intestine. 14, 15 A previous study has indicated that the Th2-dominant status plays a critical role in the inhibition of cancer growth by immunotherapy. 16 Based on the information above, we hypothesized that administration of SEB together with an SqC antigen (Ag) might generate a specific anti-SqC immune response. To test this hypothesis, we created an SqC mouse model. SqC growth was markedly inhibited after treatment with the SEB/SqC Ags,via a mechanism involving the induction of an anti-tumor T helper-9 (Th9) response.
MATERIALS AND METHODS

Reagents
Antibodies targeting signal transducer and activator of transcription 5 (STAT5), phosphorylated STAT5 (pSTAT5), PU.1, histone deacetylase-1 (HDAC1), and IL-9 were purchased from Santa Cruz (Shanghai, China). The neutralizing anti-IL-9 antibody and ELISA kits to detect IL-4, interferon gamma (IFN-c), IL-9, and IL-10 were purchased from R&D Systems (Shanghai, China). The Foxp3 ELISA kit was purchased from Shanghai Enzyme-linked Biotechnology Co., Ltd (Shanghai, China). Sigma-Aldrich (Shanghai, China). The Chromatin Immunoprecipitation Kit and protein A/G agarose were purchased from Sigma-Aldrich. Trichostatin A (TSA) and JQ1 were purchased from Selleck (Shanghai, China). The reagents for RT-qPCR and western blotting were purchased from Invitrogen (Shanghai, China). The magnetic cell sorting (MACS) kits were purchased from Miltenyi Biotech (Shanghai, China).
Cancer cell culture Squamous cell carcinoma (SCC) VII cells (a spontaneously arising squamous cell carcinoma cell line from C3H mice; maintained in our laboratory) were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum, 100 U mL 21 penicillin, 0.1 mg mL 21 streptomycin, and 2 mM L-glutamine. The medium was changed every 2 or 3 days. Prior to use in experiments, the viability of the cells was assessed via the trypan blue exclusion assay and determined to be greater than 99%.
The preparation of cancer antigen and the mixture of SEB/antigen SCC VII cells (a SqC cell line) were harvested from cultures and lysed with a lysis buffer (0.216% beta-glycerophosphate, 0.19% sodium orthovanadate, 0.001% leupeptin, 10% Triton-X-100, 3.15% Tris-HCl, 8.8% sodium chloride, 0.29% sodium ethylenediaminetetraacetic acid, and 1.12% sodium pyrophosphate decahydrate). The proteins in the lysates were quantified with Bio-Rad protein assay reagents and used as the SqC antigens. For the immunotherapy, a mixture of SqC extracts and SEB was prepared at a ratio of 25:1 (50 mg SqC extracts and 2 mg SEB per mouse per dose).
Animal SqC model development Ninety-six female C3H/HeN mice (6-8 weeks old) were purchased from the Nanjing University Experimental Animal Institute (Nanjing, China). The mice were randomly divided into eight groups as denoted in Figure 1 . The animals were 
SqC immunotherapy
The SqC-bearing mice were treated (intraperitoneal (ip) injection) with SEB (2 mg/mouse/day) and/or SqCAg (SqC antigen (the protein extracts of SCC VII cells; 50 mg/mouse/day)). A group of SqC-bearing mice were treated with SEB/SqCAg and the anti-IL-9 neutralizing antibody (100 mg/mouse; ip on days 8, 12, and 16). Another group of SqC-bearing mice were treated with SEB/SqCAg and a control antibody (IgG isotype, 100 mg/ mouse; ip on days 8, 12, and 16).
Enzyme-linked immunosorbent assay (ELISA)
The cytokine levels of IL-4, IFN-c, IL-9, IL-10, and Foxp3 were determined by ELISA with commercial reagent kits, following the manufacturer's instructions.
Cell isolation from SqC tissue
The SqC tissue was excised from SqC-bearing mice and cut into small pieces (approximately 2 3 2 3 2 mm) and incubated with collagenase IV (0.5 mg mL
21
) for 2 h at 37 uC with mild agitation. The cells were passed through a cell strainer (40 mm) and collected by centrifugation at 1500 rpm for 5 min. A portion of the single cell suspension was analyzed by flow cytometry. For SqC cell isolation, T cells, B cells, DCs, mast cells, eosinophils, fibrocytes, and NK cells were selected by MACS; the remaining cells were used as SqC cells in other experiments.
Flow cytometry CD4
1 T cells(10 6 cells/sample) were blocked with 1% bovine serum albumin (BSA) for 30 min and incubated with fluorochrome-labeled antibodies of interest or the IgG isotype (used as a negative staining control). For intracellular staining, the cells were fixed and permeabilized for 2 h and then stained with the fluorochrome-labeled antibodies of interest or the IgG isotype. After washing, the cells were analyzed by flow cytometry. At least 100 000 cells were analyzed for each sample. The data were analyzed with the Flowjo software,withthe IgG isotypestained cells as the gating reference.
T-cell proliferation assay CD4 1 CD25 2 T cells were isolated from the SqC tissue or the spleen by MACS and labeled with carboxyfluorescein succinimidyl amino ester (CFSE). The cells were cultured in the presence of phorbol-12-myristate-13-acetate (PMA; 40 ng mL ). Three days later, the cells were analyzed by the CFSE-dilution assay in a flow cytometer (FACSCanto II, BD Biosciences, Shanghai, China).
Western blotting
The cells were lysed for western blotting in a protein lysis buffer. Nuclear extracts were obtained using a NE-PER cell fractionation kit (Thermo Scientific, Shanghai, China). The cell lysates or nuclear proteins were fractionated on a 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred onto a polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with 5% skim milk for 30 min, incubated with the primaryantibodies (0.2 mg mL
21
) overnight at 4 uC, and then incubated with the secondary antibodies (labeled with horseradish peroxidase) for 1 h. Washes with Tris-buffered saline with Tween 20 were performed after each incubation. The immunoblots on the membrane were developed with an enhanced chemiluminescence kit. The results were photographed with a KODAK Image Station 4000Pro (KODAK, Shanghai, China).
Co-immunoprecipitation analysis (Co-IP)
The cells were lysed in Co-IP buffer; then, the lysates were precleared with 50 mL of pansorbin cells (Calbiochem, Shanghai, China) for 2 h, and this was followed by centrifugation. The samples were precleared by incubation with protein G agarose beads for 2 h at 4 uC. Two micrograms of anti-PU.1, anti-STAT5, anti-HDAC1, or the IgG isotype (negative control) was added to the precleared lysates in the presence of protein G agarose beads and incubated at 4 uC overnight. The immune complexes on the beads were eluted with an elution buffer and separated by SDS-PAGE, transferred to a PVDF membrane, and immunoblotted with antibodies targeting PU.1, STAT5, or HDAC1. The subsequent analysis followed the western blotting procedures.
Real-time quantitative PCR (RT-qPCR)
Total RNA was extracted from CD4 1 T cells using TRIzol reagent. The cDNA was synthesized with a Reverse Transcription Kit according to the manufacturer's instructions. The PCR was performed with a Bio-Rad MiniOpticon Real-Time PCR System using the SYBR Green PCR Master Mixto to obtain the Ct values. The results were calculated using the 2 2DDCt method. The relative expression levels of the target genes were calculated against the control group. The primers included: IL-9 (cttgcctgttttccatcgggandtctgtcttcatggtcggctt) and b-actin (gtgggaatgggtcagaagga and tcatcttttcacggttggcc).
Chromatin immunoprecipitation (ChIP) CD4 1 CD25 2 T cells were purified by MACS. The cells were cultured under conditions to induce Th9 polarization (Supplementary Figure S1) . The ChIP assay was performed with a commercial reagent kit following the manufacturer's instructions. Th9 cells or control cells (3 3 10 6 cells per sample) were treated with 1% formaldehyde to fix the protein-DNA complexes. Fixation was stopped by incubation with 1.25 M glycine for 5 min. The cells were lysed in a lysis buffer containing protease inhibitors and sonicated to shear the DNA into approximately 200-to 1000-bp DNA fragments. The samples were precleared with a protein G agarose/salmon sperm DNA slurry, and the immunoprecipitation analysis was performed at 4 uC overnight using an anti-PU.1 Ab or the IgG isotype (negative control) in the presence of protein G agarose beads. The immune complexes on the beads were eluted with an elution buffer. The DNA in the precipitated samples was recovered by reverse cross-linking at 65 uC for 4 h and analyzed by qPCR with primers targeting the Il9 promoter: forward, GGATC CTCAAGGCCAATGCT and reverse, ACACCTCTGAGAAGT CGCTC. 17 Apoptosis assay Apoptosis was assessed using Annexin V/propidium iodide (PI) staining and flow cytometry. The cells were stained with Annexin V (125 ng mL 21 ) following the manufacturer's instructions and PI (5 mg mL 21 ) for 15 min at room temperature. After washing with phosphate-buffered saline (PBS), the cells were analyzed with a flow cytometer. The Annexin V 1 cells or Annexin V 1 and PI 1 cells were regarded as apoptotic cells.
Assessment of IL-9 receptor (IL-9R) expression in cancer cells
The mouse cancer cell line SCC VII (SqC) was cultured in Dulbecco's modified Eagle medium. The expression of IL-9R in these cells was analyzed by flow cytometry (by surface staining) and western blotting. To test whether other cancer cells in addition to the SqC cells also expressed IL-9R, GL261 cells (glioma cells), and CT26 cells (colon cancer cells) were purchased from ATCC (Beijing, China). The cells were cultured and analyzed by flow cytometry and western blotting to detect the expression of IL-9R.
Statistics
The data are presented as the mean 6 SD. The difference between groups was determined by Student's t-test or analysis of variance if the analysis included more than two groups. A P , 0.05 was set as the criterion for significance.
RESULTS
Administration of SEB together with SqC Ag (SqCAg) inhibits SqC growth A mouse SqC model was developed. The mice were treated with SEB and/or SqCAg daily starting from the SqC inoculation. The tumor size was recorded every other day. The results showed that the administration of SEB/SqCAg significantly inhibited tumor growth, but this inhibition did not occur in the mice treated with either SEB or SqCAg alone (Figure 1) . The results suggest that the co-administration of SEB and SqCAg is capable of inhibiting SqC growth in mice.
Co-administration of SEB and SqCAg increases serum IL-9
The results of Figure 1 imply that the co-administration of SEB/SqCAg induces an antitumor immune response. To test this inference, we killed the SqC-bearing mice on day 20, collected their blood and isolated the sera. The sera were analyzed by ELISA. The results showed that the levels of IL-4, IFN-c, IL-10, and Foxp3 were slightly increased in the mice treated with SEB/SqCAg compared to the sera collected from the control mice (SqC-bearing mice treated with saline).However, the IL-9 levels were significantly increased ( Figure 2 ). The IL-17 and IL-21 levels were below the limit of detection (not shown). The results suggest that treatment with SEB/SqCAg may induce a Th9 response in the mice.
Co-administration of SEB and SqCAg increases IL-9 1 T cells in the SqC tissue and spleen in SqC-bearing mice We isolated CD4 1 T cells from the SqC tissues and spleens of the mice after killing. The cells were analyzed by flow cytometry. The results showed that the frequency of IL-9
1 T cells was significantly higher in mice treated with SEB/SqCAg than in mice treated with saline, SEB alone, or SqCAg alone. However, the frequency of IL-4 and IFN-c in mice treated with SEB/ SqCAg was only slightly increased compared with that of mice treated with saline (P . 0.05). Moreover, the frequencies of IL-10 1 T cells and Foxp3 1 T cells were higher in the SqC tissues of mice treated with saline than in mice treated with SEB/SqCAg (Figure 3) . The results support the inference that treatment with SEB/SqCAg induces Th9 cells in SqC-bearing mice.
The IL-9 1 T cells induced by SEB/SqCAg are SqC-specific To elucidate whether the induced Th9 cells in SqC-bearing mice were SqCAg-specific, we performed a CFSE dilution assay Figure 1 , we performed an additional experiment in which the SqC-bearing mice were treated with SEB/ SqCAg in combination with a neutralizing anti-IL-9 antibody and found that the inhibitory effect on SqC growth was abolished ( Figure 1 ).
Inhibitory effects of Th9 cells on SEB/SqCAg-induced SqC growth
To test the effect of Th9 cells on the inhibition of SqC growth, we re-performed the experiment depicted in Figure 1 . The SqCbearing mice were treated with SEB/SqC Ag plus a neutralizing anti-IL-9 antibody (ip). As expected, the inhibition of SqC growth was abolished. To strengthen the results, a group of SqC-bearing mice were adoptively transferred with in vitrogenerated SqC-specific Th9 cells (Supplementary Figure S1) , which also inhibited SqC growth (Figure 1 ).
SEB induces IL-9 expression in CD4
1 T cells SEB can activate STAT5 18 and HDAC1. 19 We inferred that STAT5 phosphorylation might be induced during the process of SEB-induced IL-9 expression in CD4 1 T cells. To test this inference, we assessed the levels of STAT5 and pSTAT5 in CD4 1 T cells. The results showed that both STAT5 and pSTAT5 could be detected in CD4 1 T cells. Exposure to SEB did not significantly alter the levels of STAT5, but pSTAT5 was markedly increased in an SEB dose-dependent manner.
A previous study has indicated that STAT5 interacts with HDAC1 to regulate target gene transcription. 20 Thus, we inferred that the SEB-activated STAT5 might bind HDAC1 and the IL-9 transcription factor PU.1 to form a complex. To test this hypothesis, we performed an immunoprecipitation assay with the CD4 1 T-cell extracts after exposure to SEB. The results showed the detection of a triple complex of STAT5, HDAC1, and PU.1 (Figure 5b) .
Next, we investigated whether this complex (Figure 5b ) bound to the il9 promoter. As shown by the ChIP assay, the IL-9 transcription factor PU.1 bound to the il9 promoter in an SEB dose-dependent manner. Because STAT5 and HDAC1 form a complex with PU.1 after exposure to SEB, we inferred that STAT5 and HDAC1 are required for the SEB-induced binding of PU.1 to the il9 promoter. To test this inference, we added a STAT5 inhibitor or HDAC1 inhibitor to the culture in addition to SEB. Indeed, the il9 promoter-binding activity of PU.1 was abolished by either the STAT5 or HDAC1 inhibitor (Figure 5c ).
We also assessed the effect of SEB on the regulation of IL-9 expression in CD4 1 T cells by RT-qPCR and western blotting. The results showed that exposure to SEB markedly induced IL-9 expression by the cells at both the mRNA and protein levels; this increase was inhibited by the presence of either the STAT5 or HDAC1 inhibitor (Figure 5d and e) .
Ag-specific Th9 cells induce SqC cell apoptosis
To test the inhibitory effect of the Ag-specific Th9 cells on the SqC cells, we generated Ag-specific Th9 cells (Supplementary Figure S1) . The Th9 cells were cultured with the SqC cells for 24 h. As analyzed by flow cytometry, the Th9 cells markedly induced SqC cell apoptosis (Figure 6a, b, and g ). The apoptosis was abolished by the presence of a neutralizing anti-IL-9 antibody (Figure 6c-g ) and was mimicked by ip injection with recombinant IL-9 (Figure 6d-g ). In contrast, naïve CD4 1 T cells did not induce SqC cell apoptosis (Figure 6e-g) . Additionally, the SqC-specific Th9 cells were not capable of inducing apoptosis in other cancer cells (CT26 colon cancer cell line) (Figure 6f and g ). These results were enforced by the finding that the SqC cells (SCC VII cells) expressed the IL-9R (Figure 6h-k) . Although other cancer cell lines (CT26 cells and GL261 cells) also expressed the IL-9R (Figure 6h-k) , these cell lines did not induce the release of IL-9 into the culture supernatant by SqC-specific Th9 cells (Figure 6l ).
DISCUSSION
Although cancer research has rapidly advanced over the last few decades, the therapeutic efficacy of cancer treatments is currently still poor. Thus, finding an efficient therapeutic treatment is of significance. The present data show that SEB may function as a potential agent to facilitate specific immunotherapy for SqC. The data indicate that co-administration of SEB and SqCAg dramatically inhibits SqC growth in a mouse model. The underlying mechanism involves the induction of SqC-specific Th9 cells by SEB and SqCAg, the latter of which is capable of inducing SqC cell apoptosis.
Th9 cells belong to the effect or T cells and release cytokines (i.e., IL-9) to regulate immune responses. Dardalhon et al. have indicated that Th9 cells do not have a suppressive function but promote tissue inflammation, such as colitis and neuritis. 21 Staudt et al. have reported that Th9 cells are involved in the pathogenesis of asthma. 22 Vegran's study has shown that Th9 cells are capable of inhibiting cancer growth. 23 Our data are in line with Vegran's report because we show that Th9 cells inhibit SqC growth and induce SqC cell apoptosis. Importantly, the results show that the induced Th9 cells are SqC-specific. These Th9 cells are activated by exposure to the specific Ag (SqC cell extracts) or SqC cells. Moreover, the results suggest that cancer-specific Th9 cells can be generated in vitro and can be adoptively transferred into cancer-bearing subjects. The cancer tissue is a source of the cancer-specific Ag that is needed to activate the transferred Ag-specific Th9 cells. This inference is supported by the data that adoptively transferred SqC-specific Th9 cells markedly inhibit SqC growth. 24 Staudt et al. have indicated that interferon-regulatory factor 4 is essential for the developmental program of Th9 cells. 22 Liao et al. have indicated that IL-2-JAK3-STAT5 signaling is required for Th9 differentiation. 25 Our data describe a novel pathway to generate Th9 cells by exposing CD4
1 T cells to SEB. SEB is a superantigen that can activate T cells via cross-linking the T-cell receptors of effector T cells and MHC II on DCs. Dhaliwal et al. have indicated that SEB increases the expression of defensin, thus strengthening innate immunity. 26 Our data reveal that SEB can also inhibit SqC growth in mice. Additionally, the data show that Th9 cell differentiation can be induced by SEB without the presence of TGF-b and IL-4.
Our results reveal the signal transduction pathway by which SEB induces the differentiation of Th9 cells. STAT5, HDAC1, and PU.1 are important molecules that mediate the SEB signal to induce Th9 cell induction. Lee et al. have indicated that STAT5 is important for Th9 cell differentiation. 25 Our data also show that STAT5 is required for the induction of Th9 cells. Additionally, HDAC1 is required for Th9 cell differentiation, and the transcription factor PU.1 is important for Th9 cell induction in our study.
The data show that SEB enforces the development of antiSqC immune responses. Previous reports have also indicated that SEB is associated with the pathogenesis of allergic disorders. The clinical study of Liu et al. has shown that SEB is associated with patients with allergic asthma and allergic rhinitis. 27 Orfali et al. have indicated that Staphylococcus aureus is present in 80%-100% of skin samples from atopic patients and is related to worsening of the disease by the action of enterotoxins. 28 Our previous work has indicated that SEB acts as an adjuvant in the development of a food allergy mouse model. 14 We have also found that SEB is decomposed into small peptides in the digestive tracts of patients with food allergies, and then the SEB peptides act as haptens, facilitating the development of food allergies. 15 These studies suggest that the use of SEB as an adjuvant may evoke a severe allergic reaction. To avoid a possible adverse reaction and maintain the immune system to ensure the efficacy of the immunotherapy, we reduced the dose of SEB from 10 mg/mouse in the food allergy study 14 to 2 mg/ mouse in the present study. Indeed, no severe allergic reactions were observed in the mice. This strategy may be used in the design of future clinical studies. In summary, the present data show that SEB can facilitate the induction of SqC-specific Th9 cells in SqC-bearing mice. Exposure to SqCAg or SqC cells induces SqC-specific Th9 cells to release IL-9; the IL-9 also mediates the induction of SqC cell apoptosis. The data suggest that SEB has the potential for use in the treatment of SqC.
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